We evaluated the incidence of renal adverse events and estimated glomerular filtration rate in patients with Philadelphia chromosome-positive leukemias receiving first-line bosutinib (n [ 248) or imatinib (n [ 251), or second-line or later bosutinib (n [ 570). Results show that long-term bosutinib treatment is associated with an apparently reversible decline in renal function with frequency and characteristics similar to those observed with long-term imatinib. Background: The purpose of the study was to assess renal function in patients with Philadelphia chromosomepositive leukemias receiving bosutinib or imatinib. Patients and Methods: Patients received first-line bosutinib (n ¼ 248) or imatinib (n ¼ 251; phase III trial), or second-line or later bosutinib (phase I/II trial; n ¼ 570). Adverse events (AEs) and changes from baseline in estimated glomerular filtration rate (eGFR) and serum creatinine were assessed. Results: Time from the last patient's first dose to data cutoff was ! 48 months. Renal AEs were reported in 73/570 patients (13%) receiving second-line or later bosutinib, and in 22/248 (9%) and 16/251 (6%) receiving first-line bosutinib and imatinib, respectively. eGFR in patients receiving bosutinib declined over time with more patients developing was not a significant predictor of Grade ! 3b eGFR. Conclusion: Long-term bosutinib treatment is associated with an apparently reversible decline in renal function with frequency and characteristics similar to renal decline observed with long-term imatinib treatment. Patients with risk factors for Grade ! 3b eGFR should be monitored closely.
Introduction
Although generally well tolerated, tyrosine kinase inhibitors (TKIs) are associated with adverse events (AEs). [1] [2] [3] [4] [5] Renal toxicity has been reported during TKI treatment for Philadelphia chromosome-positive (Ph þ ) leukemias 2, [6] [7] [8] [9] [10] [11] [12] [13] ; however, information is mostly limited to case reports. [7] [8] [9] [11] [12] [13] [14] Because of the long-term nature of TKI therapy and the different kinetics observed, particularly with regard to nonhematologic toxicities, a better understanding of the renal safety profiles of TKIs is important for optimizing patient management. Bosutinib (Bosulif; SKI-606) is an oral TKI approved in the United States for treatment of Ph þ chronic phase (CP), accelerated phase (AP), and blast phase (BP) chronic myeloid leukemia (CML) resistant/intolerant to previous TKI therapy and in Europe for treatment of Ph þ CML in patients previously treated with ! 1 TKI and for whom other TKIs are not considered appropriate. 2, 15 Bosutinib has a manageable safety profile in patients with all phases of CML, with predominantly low-grade gastrointestinal toxicities most commonly reported. [16] [17] [18] [19] [20] [21] Only a small portion (< 4%) of bosutinib is recovered in the urine, and excretion of unchanged bosutinib is low at approximately 1%, indicating minimal renal clearance of the active drug. 22 However, bosutinib administration has been associated with a decline in estimated glomerular filtration rate (eGFR) and dose adjustments are recommended in patients with baseline and treatment-emergent renal impairment. 5 In this study, renal function was comprehensively analyzed in Ph þ leukemia patients enrolled in 2 large clinical studies [16] [17] [18] receiving either bosutinib as first-line treatment (randomized vs. imatinib) or as second-line or later therapy after failure of ! 1 TKI. The objectives were to assess the extent and time course of renal dysfunction, to identify predictors of Grade ! 3b eGFR in bosutinib-treated patients, and to evaluate reversibility of treatment-emergent eGFR decline. Additionally, the effect of Grade ! 3b eGFR on the efficacy of bosutinib across treatment lines was evaluated.
Patients and Methods

Study Design and Patients
This retrospective analysis included data from 2 open-label, multinational studies. The first is a 2-part, phase I/II study of bosutinib (starting dose, 500 mg/d [part 2]) in patients with Ph þ CP CML resistant/intolerant to ! 1 previous TKI (n ¼ 403 [n ¼ 284 second-line and n ¼ 119 third-or fourth-line]), or AP CML (n ¼ 79), BP CML (n ¼ 64), or acute lymphoblastic leukemia (n ¼ 24) after previous TKI therapy. 16 The second is a phase III study of patients with newly diagnosed Ph þ CP CML treated with bosutinib 500 mg/d (n ¼ 248) or imatinib 400 mg/d (n ¼ 251). 17 Data are from unlocked trial databases with data cutoff dates of May 23, 2014 (phase I/II study) and November 21, 2013 (phase III; applied to the March 14, 2014 snapshot).
Patients were required to have adequate renal function (creatinine 1.5 times the upper limit of normal [ULN]); those with significant preexisting conditions were excluded. 16, 17 Renal Toxicity Assessments
Renal toxicity was assessed on the basis of treatment-emergent AEs (TEAEs) and laboratory parameters reported at each visit and for 28 days (phase III study) or 30 days (phase I/II study) after the last dose of study drug (for details, see the Supplemental Methods section of the Supplemental Material in the online version). Laboratory end points included serum creatinine and eGFR (calculated using the Modification of Diet in Renal Disease formula and graded on the basis of the Kidney Disease Improving Global Outcomes criteria). 23 Normal/high eGFR and mildly to moderately decreased eGFR encompassed Grades 3a (! 45 mL/min/1.73 m 2 ); moderately to severely decreased eGFR included Grades ! 3b (< 45 mL/min/1.73 m 2 ).
24-26
Renal Safety and Efficacy Analyses and Statistical Methods
Treatment-emergent AEs are reported descriptively according to disease stage (CP vs. advanced) for the phase I/II study and according to treatment (bosutinib vs. imatinib) for the phase III study; baseline characteristics are described in patients with and without Grade ! 3b eGFR. Changes from baseline in eGFR and serum creatinine levels are reported for the safety population (received ! 1 dose of study treatment) and for patients whose bosutinib dose was reduced (400 mg/d) or escalated (600 mg/d). The effect of dose reductions/escalations on changes from baseline in eGFR were compared with that in matched control participants who received 500 mg/d during their entire course of treatment. Matching was on the basis of age (within 10 years), baseline eGFR category (Grades 1-5), and treatment duration (within 6 months). On-treatment changes in creatinine levels were assessed in bosutinib-treated patients (combined studies) with baseline creatinine levels > ULN versus ULN (as specified by the local laboratory).
Baseline and on-treatment time-dependent predictors of time to Grade ! 3b eGFR were assessed using forward selection from Cox proportional hazard regression models. Forward entry criteria was P ¼ .20. Two analyses were performed, one combining all bosutinib data from CP CML patients in both studies, and another from patients receiving only first-line bosutinib and imatinib. P values were not adjusted for multiple testing.
Response was assessed in patients before and after first Grade ! 3b eGFR and for patients who did not experience Grade ! 3b eGFR. Complete cytogenetic response (CCyR) and major cytogenetic response (MCyR) were determined using standard cytogenetics with ! 20 metaphases counted for postbaseline assessments. If < 20 metaphases were available postbaseline, fluorescence in situ hybridization analysis of bone marrow aspirate or peripheral blood with ! 200 cells for the presence of breakpoint cluster region-Abelson kinase 1 fusion gene was used.
Results
Patients
Demographic and baseline clinical characteristics are presented in Table 1 . Of 56 bosutinib-treated patients with baseline creatinine levels > ULN, only 4 were newly diagnosed with CML. Median (range) treatment duration in the phase I/II trial was 18. 23-87.7] months). In the phase III study, the median (range) duration of first-line bosutinib and imatinib treatment was 54.4 (0.03-69.1) and 49.5 (0.5-62.6) months, respectively. Time from the last patient's first dose to data cutoff was ! 48 months (both studies). 
Assessment of Renal TEAEs
Thirteen percent (n ¼ 73 of 570) of patients who received second-line or later bosutinib experienced renal TEAEs (any Grade, all causality); 5% (n ¼ 29 of 570) of patients experienced renal events considered treatment-related by the investigator (Table 2) . Similar frequencies of renal TEAEs were observed across disease stages; however, with a shorter duration of treatment, exposureadjusted incidence rates (EAIRs) were higher in patients with advanced leukemias (see Supplemental Table 1 in the online version). Among the 73 relapsed/refractory patients who experienced renal TEAEs, 14 (19%) had a medical history of renal events. Grade ! 3 renal TEAEs were experienced by 10 of 403 (2%) CP CML and 7 of 167 (4%) advanced patients; 1 CP CML patient died because of acute renal failure unrelated to treatment (see the Supplemental Methods section of the Supplemental Materials in the online version). In the first-line setting, 9% (n ¼ 22 of 248) of bosutinib-treated and 6% (n ¼ 16 of 251) of imatinib-treated patients experienced renal TEAEs (any Grade, all causality); treatment-related renal events were equally uncommon in both arms (3% [n ¼ 8] each). EAIRs were also similar with both treatments (Table 2 and see Supplemental Table 1 in the online version). None of the newly diagnosed patients who experienced renal TEAEs had a medical history of renal events. Five of 248 (2%) patients experienced Grade 3 renal TEAEs in the bosutinib arm versus no patients in the imatinib arm (no Grade ! 4 events were reported in either arm). Only 2 patients underwent on-treatment hemodialysis, both in the second-line setting (see the Supplemental Methods section of the Supplemental Materials in the online version).
Renal TEAEs (any Grade) with second-line or later bosutinib resolved in 46% (24 of 52) of patients with CP CML and 48% (10 of 21) with advanced disease (Table 2 ). In patients receiving first-line bosutinib or imatinib, renal events resolved in 55% (n ¼ 12 of 22) and 63% (n ¼ 10 of 16) of patients with events, respectively. Among patients with renal events, median (range) time to first renal AE and cumulative duration of events with second-line or later bosutinib was 29 (1-1176) days and 38 (5-1406) days, respectively, for patients with advanced leukemias versus 497 (1-2695) days and 128 (1-1167) days with CP CML. Corresponding median times to first event with first-line bosutinib and imatinib were 421 
Assessment of eGFR and Serum Creatinine Levels
Twenty-four percent (n ¼ 139 of 570) of patients who received second-line or later bosutinib and 10% each of bosutinib-(n ¼ 26 of 248) and imatinib-treated (n ¼ 25 of 251) patients in the firstline setting developed Grade ! 3b eGFR, with a median (range) time to first occurrence of 23 (2-1869), 265 (6-1764), and 589 (7-1763) days, respectively. Incidences over time are presented according to disease stage (phase I/II study) and treatment (phase III study) in Supplemental Figure 1 in the online version. Median (range) duration of treatment after the first occurrence of Grade ! 3b eGFR was 347 (0-2684) days in relapsed/refractory patients, 839 (22-1798) days in bosutinib-treated, and 513 (0-1479) days in newly diagnosed imatinib-treated patients. Table 1 Continued Phase I/II (Second-Line or Later Bosutinib; CP and Advanced)
Phase III (First-Line; CP CML)
19 ( (7) 15 (14) 4 (7) 1 (6) 7 (13) 4 (36) 16 (12) 6 (17) 7 (3) 2 (8) 10 (4) 3 (12) Hyperuricemia 45 (15) 16 (15) 10 (16) 2 (12) 8 (15) 2 (18) 23 (18) 8 (23) 33 (15) 5 (19) 42 (19) 5 (20) Values are presented as n (%) unless noted otherwise. eGFR was calculated on the basis of the Modification in Diet in Renal Disease method. Terms used to identify events of hypertension were the high-level group terms vascular hypertensive disorders and cardiac and vascular investigations (excluding enzyme tests), the HLT vascular tests not elsewhere classified (including blood pressure), and the PTs abnormal blood pressure, abnormal ambulatory blood pressure, increased ambulatory blood pressure, abnormal diastolic blood pressure, increased diastolic blood pressure, increased blood pressure, abnormal systolic blood pressure, and increased systolic blood pressure.
d
Terms used to identify events of renal impairment/failure were the PTs acute prerenal failure, anuria, crush syndrome, diabetic end stage renal disease, neonatal anuria, oliguria, pancreatorenal syndrome, postrenal failure, prerenal failure, renal failure, acute renal failure, chronic renal failure, neonatal renal failure, renal impairment, neonatal renal impairment, scleroderma renal crisis, abnormal blood creatinine, increased blood creatinine, abnormal creatinine renal clearance, decreased creatinine renal clearance, abnormal glomerular filtration rate, and decreased glomerular filtration rate.
Jorge E. Cortes et al
Clinical Lymphoma, Myeloma & Leukemia October 2017 -687
Decreases from baseline in eGFR and increases in serum creatinine were observed over time in both studies. Median changes from baseline in eGFR at 48 months were À10.51 mL/min/1.73 m 2 with second-line or later bosutinib, À15.62 mL/min/1.73 m 2 with firstline bosutinib, and À17.69 mL/min/1.73 m 2 with first-line imatinib ( Figure 1A) ; median increases in serum creatinine at 48 months were 11.49, 11.49, and 13.00 mmol/L, respectively ( Figure 1B) . In both studies, no consistent trend toward higher ontreatment creatinine levels was seen over time in patients with baseline levels > ULN versus ULN; however, patient numbers were small in the > ULN group (see Supplemental Figure 2 in the online version). Most shifts from baseline in eGFR were of 1 Grade level from baseline (see Supplemental 
Reversibility of eGFR Decline
Of 139 patients who received second-line or later bosutinib who developed Grade ! 3b eGFR, 50 (36%) showed improvement to Grade 3a with no return to Grade ! 3b as of the most recent assessment recorded, 25 (50%) and 38 (76%) of whom, respectively, had dose reductions or delays because of AEs (mostly other, nonrenal AEs). Fifty-eight of the 139 patients (42%) improved to Grade 3a but subsequently returned to Grade ! 3b, whereas 31 (22%) patients did not improve from Grade ! 3b (Table 3) . Ultimately, 74 of the 139 patients (53%) returned to Grade 3a as of their last follow-up assessment. Forty-three of the 139 patients (31%) discontinued because of AEs, of whom only 7 discontinued because of renal AEs (reported as increased blood creatinine [n ¼ 3], renal failure [n ¼ 3], and renal impairment [n ¼ 1]).
Among patients who received first-line bosutinib versus imatinib who developed Grade ! 3b eGFR, similar proportions (35% [n ¼ 9 of 26] vs. 36% [n ¼ 9 of 25]) had improvement to Grade 3a with no return to Grade ! 3b. More patients who received bosutinib had dose reductions (n ¼ 5 vs. n ¼ 2) and/or dose delays (n ¼ 6 vs. n ¼ 3) because of TEAEs (renal as well as nonrenal). Improvement to Grade 3a with subsequent return to Grade ! 3b was observed in 15 of the 26 bosutinib-treated patients (58%) versus 10 of the 25 imatinib-treated patients (40%); 2 (8%) versus 6 (24%) patients, respectively, did not improve from Grade ! 3b. Ultimately, 58% and 60% of the 26 and 25 patients (n ¼ 15 in each arm), respectively, returned to Grade 3a as of their last follow-up assessment. None of the patients who received first-line bosutinib or imatinib discontinued treatment because of renal AEs (Table 3) .
Effects of Bosutinib Dose on Renal Function
Median changes from baseline in eGFR over time for patients with bosutinib dose reductions (to 400 mg/d) or escalations (to 600 mg/d) are presented in Supplemental Figure 3 in the online version. For interpretability, changes were compared with age, treatment duration, and baseline eGFR matched control patients who continued treatment at 500 mg/d. In the second-line or later setting, median changes from baseline in eGFR at 48 months were similar in patients who received a dose reduced to 400 Figure 3B in the online version). In both studies, median time to bosutinib dose reduction was < 60 days.
In the second-line or later setting, median changes from baseline in eGFR at 48 months appear lower in patients whose dose was escalated (À7.65 mL/min/1.73 m 2 ) to 600 mg/d compared with matched controls (À17.02 mL/min/1.73 m 2 ); however, creatinine data at month 48 were available for < 20 patients in each group (see Supplemental Figure 3A in the online version). In the firstline setting, a median change of À17.67 mL/min/1.73 m 2 was observed at month 48 in patients who received a dose escalation compared with À15.43 mL/min/1.73 m 2 for matched control participants; however, creatinine data at month 48 were available for only 11 patients in each group (see Supplemental Figure 3B in the online version). Median time to dose escalation was 128 days with second-line or later bosutinib and 696 days with first-line bosutinib.
Prognostic Factors for Time to Grade ! 3b eGFR Decline
In the pooled analysis of data from bosutinib-treated CP CML patients in both studies, baseline factors associated with development of Grade ! 3b eGFR (all P < .05) were older age, lower eGFR (both continuous), having proteinuria, previous hypertension, or previous interferon (all yes vs. no; Figure 2 ). On-treatment, time-dependent prognostic factors associated with Grade ! 3b eGFR included the use of antihypertensive agents or loop diuretics, Grade 3/4 vomiting, and congestive heart failure (vs. none for all). Treatment line (first-vs. third-and fourth-line and second-vs. third-and fourth-line) was not associated with development of Grade ! 3b eGFR.
In the analysis of CP CML patients receiving first-line bosutinib or imatinib in the phase III study, baseline prognostic factors associated with development of Grade ! 3b eGFR were older age, lower eGFR (both continuous), and previous hypertension (Figure 2 ). Associated on-treatment, time-dependent prognostic factors were use of loop diuretics, amino glycosides, antihypertensive agents, and Grade 3/4 diarrhea (vs. none).
Efficacy Assessments
Of 139 patients who received second-line or later bosutinib who developed Grade ! 3b eGFR, 75 (54%) newly attained or maintained a baseline MCyR (CCyR in 62 [45%]) after Grade ! 3b eGFR. Thirty-six (26%) and 35 (25%) of these patients, respectively, had their initial MCyR or CCyR after the first occurrence of Grade ! 3b eGFR; 39 (28%) and 27 (19%) patients attained/ maintained MCyR or CCyR before and after the first occurrence of Grade ! 3b eGFR. Only 5 of the 139 patients (4%) lost their previously attained MCyR; these patients continued treatment a median of 140 (range, 0-247) days after onset of Grade ! 3b eGFR. Of 428 patients who had not experienced Grade ! 3b eGFR, 192 (45%) attained or maintained MCyR (CCyR in 155 [36%]). Eighty-five percent (n ¼ 22 of 26) and 84% (n ¼ 21 of 25) of patients who received first-line bosutinib or imatinib, respectively, newly attained or maintained a CCyR after developing on-treatment Grade ! 3b eGFR. Nine (35%) and 4 (16%) of these patients, respectively, had their initial CCyR after the first Grade ! 3b eGFR event; 13 (50%) and 17 (68%) maintained a CCyR achieved before the first Grade ! 3b eGFR event. Among 26 bosutinib-treated and 25 imatinib-treated patients, 3 (12%) and 2 (8%), respectively, lost a previously attained CCyR and continued treatment a median of 102 (range, 30-168) and 13 (range, 1-25) days after onset of 
Renal Effects
With Bosutinib in Ph + Leukemia PatientsSerious AE 7 (2) 2 (3) 3 (5) 6 (4) 6 (2) 0 Leading to withdrawal from treatment 6 (1) 1 (1) 0 1 (<1) 0 0 Treatment-related b 22 (5) 5 (6) 2 (3) 7 (4) 8 (3) 8 (3) Number of Events Per Patient, n (%) 1 29 (7) 8 (10) 5 (8) 16 (10) 14 (6) 10 (4) 2 12 (3) 2 (3) 0 2 (1) 3 (1) 3 (1) 3-5 9 (2) 1 (1) 2 (3) 3 (2) 3 (1) 3 (1) 6-9 2 (<1) 0 0 0 2 (<1) 0 Maximum Toxicity Grade, n (%) 1 19 (5) 6 (7) 1 (2) 9 (5) 11 (4) 12 (5) 2 23 (6) 3 (4) 2 (3) 5 (3) 6 (2) 4 (2) 3 8 (2) 2 (3) 2 (3) 5 (3) 5 (2) 0 4 1 ( <1) 0 2 (3) 2 (1) 0 0 5 1 ( <1 ) 0 0 0 0 0 Outcome in Patients With Events,
Renal Effects With Bosutinib in Ph + Leukemia Patients
Grade ! 3b eGFR; among 222 bosutinib-treated and 225 imatinibtreated patients who had not experienced Grade ! 3b eGFR, 173 (78%) and 181 (80%), respectively, attained CCyR.
Discussion
In this long-term analysis, patients in the first-line and relapsed/ refractory settings who received bosutinib for the treatment of Ph þ leukemias experienced a decline in renal function, as evidenced by increases from baseline in serum creatinine and decreases in eGFR. Neither the overall degree nor the cumulative rate of eGFR decline appeared to be bosutinib dose-dependent. The pattern of results suggests that the observed changes in eGFR associated with bosutinib might not be because of a direct nephrotoxic effect. However, it should be noted that in a dedicated renal impairment study in volunteers with preexisting renal impairment, 35% and 60% increases in bosutinib exposure were observed in patients with moderate (creatinine clearance 30-50 mL/min) or severe (creatinine clearance < 30 mL/min) renal impairment relative to those with normal renal function. 4 Therefore, careful monitoring remains important. Dose adjustments are recommended in patients with moderate to severe renal impairment, 4 accompanied by close response monitoring at the reduced dose.
In the first-line setting, the magnitude as well as pattern of eGFR decline with bosutinib were similar to those observed with imatinib. Importantly, for most patients who developed Grade ! 3b eGFR during bosutinib and imatinib treatment, there was an improvement in eGFR over time. A substantial proportion of patients who developed eGFR Grade ! 3b returned to, and remained at, Grade 3a during therapy regardless of treatment line, suggesting a reversible effect in at least some patients. In addition, development of Grade ! 3b eGFR does not appear to negatively affect cytogenetic response to bosutinib or imatinib.
The current analyses of baseline characteristics and treatmentrelated factors in CP CML patients might allow identification of patient populations at greatest risk for Grade ! 3b eGFR. Consistent with the age-related decline in renal function observed in the general population, 27 this risk appeared higher in older patients. Other patients potentially at risk include those with early signs of kidney dysfunction (ie, proteinuria, lower baseline eGFR) at the start of treatment and those with a history of hypertension or who required concomitant antihypertensive agents or loop diuretics.
The association of on-treatment AEs with eGFR decline was also examined; in particular, Grade 3/4 diarrhea, Grade 3/4 vomiting, any Grade infection/sepsis, and any Grade congestive heart failure were evaluated on the basis of their potential to result in hemodynamic changes that could lead to renal dysfunction. In the model pooling bosutinib data from CP CML patients in both studies, congestive heart failure, although infrequent, was associated with Grade ! 3b eGFR, which is in keeping with the reported relationship between hypertension, heart failure, and kidney disease. [28] [29] [30] Grade 3/4 vomiting (pooling both studies) and diarrhea (first-line bosutinib vs. imatinib) were also significant risk factors. As in patients taking diuretic medications, this could involve dehydration as a contributing factor. Taken together, these results suggest that patients who experience Grade 3/4 diarrhea or vomiting should be kept well hydrated. Patients who experience these events or congestive heart failure should be monitored closely for renal dysfunction.
In both studies, onset of Grade ! 3b eGFR occurred early, after which renal function decreased at a rate consistent with the physiologic decline associated with aging ( Figure 1A) . 31 This is in contrast to established models of drug-induced nephrotoxicity, where loss of renal function begins gradually then becomes more significant over time with continued treatment. 32, 33 The time to first Grade ! 3b eGFR was shorter in the study of second-line or later bosutinib, suggesting that previous TKI exposure and other factors associated with advanced disease might predispose patients to renal dysfunction. Among patients who developed Grade ! 3b eGFR, median time to onset with first-line bosutinib was less than half that of imatinib, although the overall incidence of Grade ! 3b eGFR was the same in both arms. Despite the earlier onset of eGFR decline with first-line bosutinib, median duration of bosutinib treatment after first occurrence of Grade ! 3b eGFR was comparable with that observed with first-line imatinib and with CP CML patients who received second-line or later bosutinib. Few patients with normal eGFR at baseline developed Grade ! 3b eGFR; among those who did, most subsequently improved during continued therapy. These findings suggest that factors other than bosutinib likely played a role in the decline of eGFR.
It should be noted that development of Grade ! 3b eGFR did not result in a loss of cytogenetic response. In fact, most patients (54%) who developed Grade ! 3b eGFR during bosutinib treatment in the phase I/II study either maintained an ongoing MCyR or first attained an MCyR after documentation of Grade ! 3b eGFR.
Renal dysfunction has been reported with other TKIs, including imatinib, 6-10,14,34-36 nilotinib, [37] [38] [39] and dasatinib, 6,9,11-14,40-43 suggesting a possible drug class effect. This is supported by the similar frequency and characteristics of renal decline observed with imatinib and bosutinib treatment in our analyses. Tumor lysis and toxic tubular damage have been proposed as possible mechanisms for renal failure with TKI therapy. 7, 13 Imatinib-induced tubular damage might be related to the off-target inhibition of platelet-derived growth factor receptor (PDGF-R), which regulates the proliferation and regeneration of proximal tubular cells in the kidney and is notably not targeted by bosutinib. 44, 45 However, findings from a recent study suggested that long-term treatment with imatinib, but not dasatinib or nilotinib, might cause a significant decline in eGFR. 42 Because these TKIs also inhibit PDGF-R, there is likely a more complex explanation. 45 Vidal-Petiot et al recently discovered that tubular secretion of creatinine is greatly diminished in imatinibtreated CML patients resulting in a reversible increase in serum creatinine levels. 46 Although further research is needed to understand the mechanism of this decreased tubular secretion, because the observed increase in serum creatinine was independent of any loss of glomerular function, renal function might be underestimated when using creatinine-derived formulas to calculate eGFR. Therefore, it is possible that the increased creatinine values observed with bosutinib could be due to decreased tubular secretion of creatinine, thus not reflecting a true decrease in glomerular filtration. More work is needed to determine the mechanism of renal toxicity associated with TKIs and if this toxicity is associated with inhibition in critical kidney tissues.
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Conclusions
These long-term safety analyses suggest that the benefit-risk profile remains favorable for bosutinib in patients with Ph þ CML. Although the follow-up duration for safety data collection upon treatment discontinuation was 30 days for both studies, the treatment benefit of bosutinib likely outweighs the risk of developing renal dysfunction in most Ph þ leukemia patients. However, patients treated with TKIs should be monitored for renal function at baseline and during therapy, with particular attention paid to those who have preexisting renal impairment or associated risk 32 (31) 8 (47) 1 (9) 11 (31) 5 (19) 1 (4) Renal AE Events leading to discontinuation were abdominal adhesions, abdominal pain, anemia, ascites, atrial fibrillation, back pain, coronary artery disease, cough, diarrhea, fluid retention, hemoglobin decreased, hypersensitivity vasculitis, intestinal ischemia, intestinal obstruction, liver function test abnormal, myocardial infarction, renal impairment, pancytopenia, pericardial effusion, pericarditis, pneumonia, and pulmonary hypertension (all n ¼ 1), as well as blood creatinine increased and serositis (n ¼ 2), cardiac failure, renal failure, and vomiting (all n ¼ 3), thrombocytopenia, dyspnea, and pleural effusion (all n ¼ 4) in patients with CP CML; alanine aminotransferase increased, amylase increased, blood alkaline phosphatase increased, blood creatinine increased, chest pain, coronary artery disease, disease progression, dyspnea, lipase increased, pleural effusion, and serositis (all n ¼ 1), as well as pericardial effusion (n ¼ 2) in patients with AP CML; cardiac failure congestive (n ¼ 1) in the BP CML cohort; and cerebral infarction (n ¼ 1) in patients with ALL in the phase I/II study; atypical pneumonia, exfoliative rash, fluid retention, platelet count decreased, and pleural effusion (all n ¼ 1) in the bosutinib arm, and exfoliative rash (n ¼ 1) in the imatinib arm of the phase III study. e Includes the following preferred terms from the Medical Dictionary for Regulatory Activities (version 17.0): acute prerenal failure, anuria, crush syndrome, diabetic end stage renal disease, neonatal anuria, oliguria, pancreatorenal syndrome, postrenal failure, prerenal failure, renal failure, renal failure acute, renal failure chronic, renal failure neonatal, renal impairment, renal impairment neonatal, scleroderma renal crisis, blood creatinine abnormal, blood creatinine increased, creatinine renal clearance abnormal, creatinine renal clearance decreased, glomerular filtration rate abnormal, glomerular filtration rate decreased. 
Renal Effects With Bosutinib in
Clinical Practice Points
Renal toxicity has been reported during TKI treatment for Ph þ leukemias. Information on TKI-associated renal toxicity is mostly limited to case reports. A better understanding of the renal safety profiles of TKIs is important for optimizing outcomes.
Long-term bosutinib treatment appears to be associated with a reversible decline in renal function in patients with CP CML or advanced disease that is resistant or intolerant to previous TKI therapy.
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